Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.

@article{Wilkerson1993FourweekSA,
  title={Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.},
  author={M. Wilkerson and M. Cyrlin and E. Lippa and D. Esposito and D. Deasy and D. Panebianco and R. Fazio and M. Yablonski and M. B. Shields},
  journal={Archives of ophthalmology},
  year={1993},
  volume={111 10},
  pages={
          1343-50
        }
}
OBJECTIVE To investigate the activity and local and systemic safety of the topical carbonic anhydrase inhibitor, dorzolamide hydrochloride. DESIGN Four-week, double-masked, randomized, placebo-controlled, parallel, three-center study. SETTING Referral centers. PATIENTS Forty-eight patients with bilateral open angle glaucoma or ocular hypertension and intraocular pressure (IOP) greater than 22 mm Hg entered the study. Two of 28 patients receiving dorzolamide and two of 20 patients… Expand
A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study.
Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide
Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
MK-927: a topically effective carbonic anhydrase inhibitor in patients.
...
1
2
3
...